Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1 ...

Anti-tumor effects of molecular glue BC. (a) Representative images of tumors in different treatment groups after 28 days. (b) Quantifications of anti-tumor activity of compound BC in the xenograft. (c ...

A new study, led by researchers from the University of California, Irvine and the University of California, San Diego, reveals a new computation-guided approach to identify small molecules that can ...

The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...

In a recent study published in the Cell Reports journal, researchers assessed the impact of protein adduction on p53 tumor suppressor inhibition. Studies have shown that exposing esophageal cells to ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

Molecular model of the tumor suppressor protein p53 (beige) bound to a molecule of DNA (red and blue). P53 maintains genomic stability by controlling cell division, repairing DNA damage, and ...

CHICAGO -- Almost 90% of patients with metastatic liposarcoma achieved disease control with an investigational drug targeting p53 suppression, according to an early study reported at the American ...

Researchers at the University of Michigan Rogel Cancer Center and School of Dentistry found that certain drugs can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid ...

Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues. Background: CRM1 (XPO1) is a key nuclear export protein which ...